Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company, St. Louis, Missouri-based Tropichem Research Labs, LLC, is unifying its businesses under the new company name Vetio Animal Health (Vetio) effective immediately. The new name has been chosen to better reflect the Company’s exclusive focus as a Contract Development and Manufacturing Organization (CDMO) for animal health.
John Kane, CEO of Vetio (www.vetio.com), commented, “The launch of our new brand marks another significant step toward the Company’s goal of becoming the leading CDMO in animal health.” Kane added, “Our brand promise, Actualizing Animal Health, means that we work with our customers to turn their ideas into reality. Vetio is a single-source partner for successful development, technical transfers, analytical services and manufacturing.”
Tropichem acquired Tetragenx earlier this year. At that time, the Company outlined a strategy to expand its manufacturing capabilities to meet the specific needs of animal health companies. In September, it announced plans to build a non-sterile liquid facility in Montreal, Canada. The Company is also currently in the construction phase of a solid dose plant to produce pharmaceutical soft chews, tablets, and ingredients in its Montreal location. Both plants will begin commercial production in mid-to-late 2019.
